Opal is looking to out-license its portfolio of hospital product dossiers to interested Companies around the remainder of the world. All the development products are improved preparations of small molecules and are written to EU CTD format. Opal is involved in further partnerships for new technology aimed at delivering further improvements in the preparations of existing small molecules.